
NASDAQHealthcareBiotechnology
Latest quote
$12.845
−$0.755 · -5.55%
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Previous close
$12.845
−$0.755 · -5.55%
Regular session · ET · Market data may be delayed.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Day range
Current $12.845
52-week range
Current $12.845
Regular session · ET · Market data may be delayed.
GoAI Score
Hold
Valuation
33
Expensive
Sentiment
72
Bullish
Risk
52
Elevated Risk
Momentum
68
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Day range
Current $12.845
52-week range
Current $12.845
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 83.98M USD | 54.55M USD | 76.99M USD | 38.63M USD | 29.75M USD |
| Cost of goods sold | 18.86M USD | 221.63M USD | 189.15M USD | 184.5M USD | 116.43M USD |
| Gross profit | 65.12M USD | −167.08M USD | −112.16M USD | −145.87M USD | −86.68M USD |
| Research and development | 308.16M USD | 221.63M USD | 189.15M USD | 184.5M USD | 116.43M USD |
| Selling, general, and administrative | 52.74M USD | 45.94M USD | 42.9M USD | 38M USD | 31.2M USD |
| Operating expenses | 350.79M USD | 45.94M USD | 42.9M USD | 38M USD | 31.2M USD |
| Interest income | 21.97M USD | 19.73M USD | 11.12M USD | 3.51M USD | 823K USD |
| Depreciation and amortization | 18.86M USD | 16.43M USD | 13.65M USD | 10.81M USD | 6.08M USD |
| Operating income | −285.67M USD | −213.03M USD | −155.06M USD | −183.87M USD | −117.89M USD |
| Net income | −264.46M USD | −193.57M USD | −143.95M USD | −180.36M USD | −117.19M USD |
Company facts updated Nov 22, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Third-party consensus; not a GoAI recommendation.
Average target
$33.69
162.28% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI69.78M0.00%689.3B USD0.03%$340.02-3.52%
ARK Genomic Revolution ETFARKG36.09M2.08%2.21B USD0.75%$38.00-5.64%
iShares Russell 2000 ETFIWM32.95M0.05%71.54B USD0.19%$256.61-2.88%
State Street SPDR S&P Biotech ETFXBI30.56M0.32%9.64B USD0.35%$140.18-2.73%
Vanguard Extended Market ETFVXF29.77M0.03%30.2B USD0.05%$211.44-3.21%
Vanguard Russell 2000 ETFVTWO15.11M0.08%16.8B USD0.06%$103.76-2.76%
iShares Biotechnology ETFIBB9.84M0.09%10.53B USD0.44%$199.54-2.05%
iShares Russell 2000 Growth ETFIWO9.52M0.07%12.73B USD0.24%$320.43-3.57%
Vanguard Morningstar Total Stock Market ETFVTI
ARK Genomic Revolution ETFARKG
iShares Russell 2000 ETFIWM
State Street SPDR S&P Biotech ETFXBI
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Biotechnology ETFIBB
iShares Russell 2000 Growth ETFIWOAI-generated and delayed market data for informational and educational purposes only. Not investment advice.